HELIOS Kliniken

Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) (2017) Kuemmel S, Paepke S, Huober J, Schem C, Untch M, Blohmer JU, Eiermann W, et al. Journal article Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto) (2017) Untch M, Schneeweiss A, Salat C, Rezai M, Zahm DM, Klare P, Blohmer JU, et al. Conference contribution Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE) (2017) Loibl S, De La Pena L, Nekljudova V, Zardavas D, Michiels S, Denkert C, Rezai M, et al. Journal article Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study (2017) Hack C, Fasching P, Fehm T, De Waal J, Rezai M, Baier B, Baake G, et al. Journal article Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017) (2017) Untch M, Huober J, Jackisch C, Schneeweiss A, Brucker SY, Dall P, Denkert C, et al. Journal article Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial (2017) Hahnen E, Lederer B, Hauke J, Loibl S, Kroeber S, Schneeweiss A, Denkert C, et al. Journal article A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study (2017) Harbeck N, Saupe S, Jaeger E, Schmidt M, Kreienberg R, Mueller L, Otremba BJ, et al. Journal article The PAZOREAL noninterventional study to assess effectiveness and safety of pazopanib and everolimus in the changing metastatic renal cell carcinoma treatment landscape (2017) Goebell P, Doehn C, Gruellich C, Gruenwald V, Steiner T, Ehness R, Welslau M Journal article Interim results from PAZOREAL: A non-interventional study to assess effectiveness and safety of pazopanib and everolimus in the changing mRCC treatment landscape (2017) Bedke J, Welslau M, Boegemann M, Schostak M, Hering-Schubert C, Petzoldt A, Wolf T, et al. Conference contribution Analysis of the German DRG data for livedoid vasculopathy and calciphylaxis (2017) Renner R, Dissemond J, Goerge T, Hoff N, Kroeger K, Erfurt-Berge C Journal article